Advances in Chronic Kidney Disease
Volume 11, Issue 3 , Pages 294-303 , July 2004

Opportunities for improvement in the cardiovascular care of patients with end-stage renal disease

  • Peter A McCullough

      Affiliations

    • Department of Medicine, Divisions of Cardiology, Nutrition, and Preventive Medicine, William Beaumont Hospital, Royal Oak, MI, USA
    • Corresponding Author InformationAddress correspondence to Peter A. McCullough, MD, MPH, Division of Clinical Nutrition and Preventive Medicine, William Beaumont Hospital, 4949 Coolidge Highway, Royal Oak, MI 48073 USA

References 

  1. McCullough PA. Cardiorenal risk (An important clinical intersection). Rev Cardiovasc Med. 2002;3:71–76
  2. Adler AI, Stevens RJ, Manley SE, et al.  Development and progression of nephropathy in type 2 diabetes (the United Kingdom Prospective Diabetes Study (UKPDS 64)). Kidney Int. 2003;63:225–232
  3. Agarwal R, Nissenson AR, Batlle D, et al.  Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 2003;115:291–297
  4. Chobanian AV, Bakris GL, Black HR, et al.  The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560–2572
  5. Vlahakos DV, Hahalis G, Vassilakos P, et al.  Relationship between left ventricular hypertrophy and plasma renin activity in chronic hemodialysis patients. J Am Soc Nephrol. 1997;8:1764–1770
  6. Toto R. Angiotensin II subtype 1 receptor blockers and renal function. Arch Intern Med. 2001;161:1492–1499
  7. Brenner BM, Cooper ME, de Zeeuw D, et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869
  8. Lewis EJ, Hunsicker LG, Clarke WR, et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860
  9. Parving HH, Lehnert H, Brochner-Mortensen J, et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–878
  10. Dahlof B, Devereux RB, Kjeldsen SE, et al.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) (A randomised trial against atenolol). Lancet. 2002;359:995–1003
  11. Mann JF, Gerstein HC, Pogue J, et al.  Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril (The HOPE randomized trial). Ann Intern Med. 2001;134:629–636
  12. Hampl H, Sternberg C, Berweck S, et al.  Regression of left ventricular hypertrophy in hemodialysis patients is possible. Clin Nephrol. 2002;58(suppl 1):S73–S96
  13. Agodoa LY, Appel L, Bakris GL, et al.  Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis (A randomized controlled trial). JAMA. 2001;285:2719–2728
  14. Li PK, Chow KM, Wong TY, et al.  Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis (A randomized, controlled study). Ann Intern Med. 2003;139:105–112
  15. McCullough PA, Sandberg KR, Yee J, et al.  Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease. J Renin Angiotensin Aldosterone Syst. 2002;3:188–191
  16. Bakris GL. Role for beta-blockers in the management of diabetic kidney disease. Am J Hypertens. 2003;16(9 pt 2 suppl):7S–12S
  17. Cice G, Ferrara L, D’Andrea A, et al.  Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy (A prospective, placebo-controlled trial). J Am Coll Cardiol. 2003;41:1438–1444
  18. McCullough PA, Sandberg KR, Borzak S, et al.  Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J. 2002;144:226–232
  19. Porter GA, Norton TL, Lindsley J, et al.  Relationship between elevated serum troponin values in end-stage renal disease patients and abnormal isotopic cardiac scans following stress. Ren Fail. 2003;25:55–65
  20. Buemi M, Senatore M, Corica F, et al.  Statins and progressive renal disease. Med Res Rev. 2002;22:76–84
  21. Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int. 1999;71(suppl):S2–S5
  22. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  23. American Diabetes Association . Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003;26(suppl 1):S33–S50
  24. Biesenbach G, Zazgornik J. Influence of smoking on the survival rate of diabetic patients requiring hemodialysis. Diabetes Care. 1996;19:625–628
  25. Benowitz NL. Pharmacology of nicotine (addiction and therapeutics). Annu Rev Pharmacol Toxicol. 1996;36:597–613
  26. Michael Pittilo R. Cigarette smoking, endothelial injury and cardiovascular disease. Int J Exp Pathol. 2000;81:219–230
  27. Wilson K, Gibson N, Willan A, et al.  Effect of smoking cessation on mortality after myocardial infarction (Meta-analysis of cohort studies). Arch Intern Med. 2000;160:939–944
  28. Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med. 2002;162:2197–2202
  29. Winchester JF. Therapeutic uses of aspirin in renal diseases. Am J Kidney Dis. 1996;28(suppl 1):S20–S23
  30. Kaufman JS, Fiore L, Hasbargen JA, et al.  A pharmacodynamic study of clopidogrel in chronic hemodialysis patients. J Thromb Thrombolysis. 2000;10:127–131
  31. van Guldener C, Stam F, Stehouwer CD. Homocysteine metabolism in renal failure. Kidney Int. 2001;78(suppl):S234–S237
  32. Moustapha A, Naso A, Nahlawi M, et al.  Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation. 1998;97:138–141
  33. Shemin D, Bostom AG, Selhub J. Treatment of hyperhomocysteinemia in end-stage renal disease. Am J Kidney Dis. 2001;38(suppl 1):S91–S94
  34. Koenig W. Update on C-reactive protein as a risk marker in cardiovascular disease. Kidney Int. 2003;84(suppl):S58–S61
  35. Ridker PM, Cushman M, Stampfer MJ, et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979 Erratum in: N Engl J Med 337:356, 1997
  36. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998;339:799–805
  37. Shlipak MG. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med. 2003;138:917–924
  38. McCullough PA. Acute coronary syndromes in patients with renal failure. Curr Cardiol Rep. 2003;5:266–270
  39. Sica D. The implications of renal impairment among patients undergoing percutaneous coronary intervention. J Invasive Cardiol. 2002;14(suppl B):30B–37B
  40. Schreiber BD. Congestive heart failure in patients with chronic kidney disease and on dialysis. Am J Med Sci. 2003;325:179–193
  41. McCullough PA, Duc P, Omland T, et al.  B-type natriuretic peptide and renal function in the diagnosis of heart failure (an analysis from the breathing not properly multinational study). Am J Kidney Dis. 2003;41:571–579
  42. McCullough PA, Sandberg KR. B-type natriuretic Peptide and renal disease. Heart Fail Rev. 2003;8:355–358
  43. Al-Ahmad A, Rand WM, Manjunath G, et al.  Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001;38:955–962
  44. Mancini DM, Katz SD, Lang CC, et al.  Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107:294–299
  45. Shlipak MG. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med. 2003;138:917–924
  46. Schoolwerth AC, Sica DA, Ballermann BJ, et al.  Renal considerations in angiotensin converting enzyme inhibitor therapy (A statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association). Circulation. 2001;104:1985–1991
  47. Keating GM, Goa KL. Nesiritide (A review of its use in acute decompensated heart failure). Drugs. 2003;63:47–70
  48. Tamura K, Tsuji H, Nishiue T, et al.  Determinants of ventricular arrhythmias in hemodialysis patients (Evaluation of the effects of arrhythmogenic substrate and autonomic imbalance). Am J Nephrol. 1998;18:280–284
  49. De Lima JJ, Vieira ML, Lopes HF, et al.  Blood pressure and the risk of complex arrthymia in renal insufficiency (Hemodialysis and renal transplant patients). Am J Hypertens. 1999;12:204–208
  50. Herzog CA. Cardiac arrest in dialysis patients (Approaches to alter an abysmal outcome). Kidney Int. 2003;84(suppl):S197–S200
  51. The Antiarrythmics versus Implantable Defibrillators Investigators . A comparison of antiarrhythmic-drug therapy with implantable defibrillator in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576–1583
  52. Moss AJ, Zareba W, Hall WJ, et al.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883
  53. Kocheril AG. Arrhythmia issues in patients with renal disease. Semin Nephrol. 2001;21(1):57–65
  54. London GM. Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant. 2002;17(suppl 1):29–36
  55. Converse RL, Jacobsen TN, Toto RD, et al.  Sympathetic over activity in the patients with chronic renal failure. N Engl J Med. 1992;327:1912–1918
  56. Amann K, Breitbach M, Ritz E, et al.  Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol. 1998;9:1018–1022
  57. Narula AS, Jha V, Bali HK, et al.  Cardiac arrhythmias and silent myocardial ischemia during hemodialysis. Ren Fail. 2000;22:355–368
  58. Cupisti A, Galetta F, Caprioli R, et al.  Potassium removal increases the Q-Tc interval dispersion during hemodialysis. Nephron. 1999;82:122–126
  59. Wase A, Basit A, Nazir R. Does chronic renal insufficiency raise defibrillation threshold?. Pacing Clin Electrophysiol. 2002;25(4 pt II):594
  60. Gregoratos G, Abrams J, Epstein AE, et al.  A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation. 2002;106:2145–2161
  61. McCullough PA. Why is chronic kidney disease the “spoiler” for cardiovascular outcomes?. J Am Coll Cardiol. 2003;41:725–728

PII: S1548-5595(04)00078-3

doi: 10.1053/j.arrt.2004.04.009

Advances in Chronic Kidney Disease
Volume 11, Issue 3 , Pages 294-303 , July 2004

Article Tools

* Image Usage & Resolution